Infectious Disease Diagnostics Market Size & Share 2023 to 2032

Infectious Disease Diagnostics Market Size

Infectious Disease Diagnostics Market size was USD 24 billion in 2022 and will exhibit more than 5.5% CAGR from 2023-2032. Rising popularity of point-of-care diagnostic testing techniques to supplement industry growth.
 

The increasing preference for point-of-care diagnostic testing will influence the industry expansion. Rapid results obtained from point-of-care testing are increasingly crucial for prompt diagnosis and treatment in urgent care centres, emergency rooms, and ambulances. The growing need for rapid diagnosis and treatment helps to enhance patient outcomes while catering to several illnesses or infectious diseases has made way for innovations, further driving the market share.

Limited awareness pertaining to infection control and prevention as well as personal health and hygiene, specifically in the underdeveloped nations may pose as a major barrier for the demand for infectious disease diagnostics. Numerous hospitals are facing the challenges of inadequate infrastructure, such as poor water sanitation, and hygiene facilities. Lack of training among healthcare professionals for infection control in healthcare settings, staff shortages, and ineffective compliance of hospital and patient staff with hygiene standards are other factors limiting the market size.
 

Infectious Disease Diagnostics Market Analysis

Infectious disease diagnostics market share from the reagents, kits & consumables segment was over USD 12 billion in 2022. This is attributed to the abundant availability of reagents, kits, and consumables for diagnosing several infectious diseases on the basis of exact targeted pathogens and conducted diagnostic tests. The growing adoption of RT-PCR in identifying RNA viruses including influenza, SARS-CoV-2, and hepatitis C will also add to the industry landscape. 
 

Infectious disease diagnostics market from respiratory disease applications will record 6% CAGR from 2023-2032. In recent years, there has been a significant rise in the number of pathogens that cause respiratory infections include bacteria, viruses, fungi, and parasites. Chest X-rays, such as CT scans, physical exams, and laboratory tests, including PCR testing of respiratory secretions and blood are increasingly employed as diagnostic tools to treat respiratory infections. The growing prominence of these tests for determining the origin of respiratory infections and offering the best course of actions will influence the industry scenario.
 

North America infectious disease diagnostics market is estimated to exceed USD 17 billion by 2032 due to the surging frequency of infectious diseases and the scaling deployment of cutting-edge diagnostic technologies. The rising healthcare costs and the rapidly expanding ageing population mainly in the U.S., Canada and Mexico will also boost the development of the regional market.
 

Infectious Disease Diagnostics Market Share

• Abbott Laboratories
• BioMerieus SA
• Becton Dickinson and Company
• Danaher Corporation
• Bio-Rad Laboratories
• F Hoffman-La Roche
• Hologic Inc
• Qiagen Inc
• Siemens Healthineers,
• Thermo Fisher Scientific Inc

 are some of the leading infectious disease diagnostics industry market participants worldwide. These firms are actively adopting various strategies to boost their revenue sales.

Infectious Disease Diagnostics Industry News

• Bio-Rad Laboratories, in April 2022, displayed its whole line of infectious disease testing reagents, equipment, and quality controls to streamline test procedures as well as deliver high-quality findings.

The infectious disease diagnostics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million and volume in Units from 2018 to 2032 for the following segments:

By Product

• Instruments
• Reagents, kits & consumables
• Services

By Technology

• Clinical Microbiology
• Polymerase chain reaction (PCR)
• In Situ Hybridization
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Immunodiagnostics
• Other technology

By Application

• COVID-19
• Gastrointestinal Tract Infections
• Respiratory Diseases
• Sexually Transmitted Infections
• Tuberculosis
• Hospital acquied infection
• Mosquito-borne diseases
• Other Infectious Diseases

By End-use

• Hospitals
• Clinics
• Diagnostics Laboratories
• Research Institutes
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Poland
  • Switzerland
  • Sweden
  • Denmark
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey